PCM
PTCT icon

Prelude Capital Management’s PTC Therapeutics PTCT Stock Holding History

Prelude Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-145,500
Closed -$2.91M – 1635
2017
Q3 		$2.91M Buy
+145,500
New +$2.85M 0.26% 79
2017
Q2 		– Sell
-61,900
Closed -$609K – 1802
2017
Q1 		$609K Buy
61,900
+41,500
+203% +$502K 0.06% 312
2016
Q4 		$223K Buy
+20,400
New +$214K 0.03% 541

Other funds holding PTCT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Prelude Capital Management's PTCT Position: Q3 2023 in Review

Prelude Capital Management sold out of PTC Therapeutics (PTCT) in Q3 2023, closing a stake of 15,228 shares — an estimated $619K sold.

Prelude Capital Management first reported a position in PTCT in Q2 2015 and held it in 22 quarters. The position peaked at $5.17M in Q2 2017. 180 funds tracked by Wall St. Rank hold PTCT as of Q3 2023.

  • Prelude Capital Management reported no remaining PTC Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Prelude Capital Management sold 15,228 PTC Therapeutics shares in Q3 2023, an estimated $619K.
  • Prelude Capital Management first reported a position in PTC Therapeutics in Q2 2015 and held it in 22 quarters.
  • Prelude Capital Management's PTC Therapeutics position peaked at $5.17M in Q2 2017.
  • 180 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2023.

Based on Prelude Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.